CUSIP 955306105 · who reports it, how much, and how much it matters to them
41 of the 720 hedge fund managers we track reported shares of West Pharmaceutical Services Inc (NYSE: WST) on Form 13F for 30 June 2026. Between them they reported USD 1.4bn. The largest position belongs to Artisan Partners, at USD 866m. The manager with the most riding on it is Alpine Peaks Capital, where it is 8.1% of the reported book.
Compiled from SEC Form 13F filings · Hedge Fund Intelligence, PPLI.com · updated
Form 13F is filed by the manager and covers all of its accounts, so a position here belongs to the firm, not to any one fund. Not investment advice.
A list of every manager in our coverage that reported this share at the end of the quarter, taken from the filings themselves. Short positions and options are not in it.
Taken from each manager's Form 13F for 30 June 2026. A manager appears here if it reported the shares themselves; positions held only through options are left out.
The bar and the percentage show how much of the manager's reported 13F book the position makes up. Each name opens that manager's largest fund on PPLI.com, where the rest of its book is listed.
| # | Manager | Value reported | Share of its book |
|---|---|---|---|
| 1 | Artisan Partners1 fund on PPLI.com | USD 866m | 1.4% |
| 2 | Citadel Advisors32 funds on PPLI.com | USD 127m | 0.0% |
| 3 | POINT72 Asset Management17 funds on PPLI.com | USD 102m | 0.1% |
| 4 | Holocene Advisors2 funds on PPLI.com | USD 99m | 0.2% |
| 5 | Marshall Wace LLP84 funds on PPLI.com | USD 30m | 0.0% |
| 6 | Orbimed Advisors1 fund on PPLI.com | USD 25m | 0.5% |
| 7 | Adage Capital Management1 fund on PPLI.com | USD 21m | 0.0% |
| 8 | Balyasny Asset Management25 funds on PPLI.com | USD 16m | 0.0% |
| 9 | Renaissance Technologies13 funds on PPLI.com | USD 11m | 0.0% |
| 10 | Exoduspoint Capital Management7 funds on PPLI.com | USD 11m | 0.1% |
| 11 | Tudor Investment Corporation10 funds on PPLI.com | USD 8.6m | 0.0% |
| 12 | Verition Fund Management3 funds on PPLI.com | USD 7.7m | 0.0% |
| 13 | Millennium Management6 funds on PPLI.com | USD 7.6m | 0.0% |
| 14 | PFM Health Sciences3 funds on PPLI.com | USD 7.4m | 0.6% |
| 15 | Alpine Peaks Capital4 funds on PPLI.com | USD 6.9m | 8.1% |
| 16 | Engineers Gate Manager1 fund on PPLI.com | USD 6.8m | 0.1% |
| 17 | Capricorn Fund Managers8 funds on PPLI.com | USD 6.7m | 0.5% |
| 18 | Two Sigma Investments35 funds on PPLI.com | USD 6.5m | 0.0% |
| 19 | CIBC Asset Management69 funds on PPLI.com | USD 6m | 0.0% |
| 20 | IFM Investors Pty7 funds on PPLI.com | USD 5.9m | 0.0% |
| 21 | D. E. Shaw & Co.15 funds on PPLI.com | USD 4.6m | 0.0% |
| 22 | Landscape Capital Management4 funds on PPLI.com | USD 4.3m | 0.3% |
| 23 | Bridgewater Associates45 funds on PPLI.com | USD 3.7m | 0.0% |
| 24 | Cinctive Capital Management5 funds on PPLI.com | USD 2.7m | 0.1% |
| 25 | Grantham Mayo Van Otterloo & Co1 fund on PPLI.com | USD 2m | 0.0% |
| 26 | Freestone Grove Partners1 fund on PPLI.com | USD 2m | 0.0% |
| 27 | Boothbay Fund Management2 funds on PPLI.com | USD 1.8m | 0.0% |
| 28 | Caxton Associates6 funds on PPLI.com | USD 1.4m | 0.0% |
| 29 | Kinneret Advisory7 funds on PPLI.com | USD 1.4m | 0.1% |
| 30 | Dark Forest Capital Management2 funds on PPLI.com | USD 1.3m | 0.1% |
| 31 | Squarepoint Ops7 funds on PPLI.com | USD 1.2m | 0.0% |
| 32 | Entrypoint Capital1 fund on PPLI.com | USD 847,000 | 0.2% |
| 33 | Neo Ivy Capital Management1 fund on PPLI.com | USD 805,000 | 0.2% |
| 34 | Hyperion Capital Advisors2 funds on PPLI.com | USD 728,000 | 0.3% |
| 35 | Graham Capital Management18 funds on PPLI.com | USD 644,000 | 0.0% |
| 36 | Trust Asset Management4 funds on PPLI.com | USD 537,000 | 0.0% |
| 37 | Oxford Asset Management LLP2 funds on PPLI.com | USD 510,000 | 0.3% |
| 38 | Schonfeld Strategic Advisors30 funds on PPLI.com | USD 374,000 | 0.0% |
| 39 | Bayforest Capital1 fund on PPLI.com | USD 317,000 | 0.3% |
| 40 | Armistice Capital1 fund on PPLI.com | USD 208,000 | 0.0% |
| 41 | Fulcrum Asset Management LLP7 funds on PPLI.com | USD 11,350 | 0.0% |
A large manager can hold a great deal of a share and barely notice it. This table turns the question round and ranks managers by how much of their own book the position takes up.
| # | Manager | Value reported | Share of its book |
|---|---|---|---|
| 1 | Alpine Peaks Capital | USD 6.9m | 8.1% |
| 2 | Artisan Partners | USD 866m | 1.4% |
| 3 | PFM Health Sciences | USD 7.4m | 0.6% |
| 4 | Capricorn Fund Managers | USD 6.7m | 0.5% |
| 5 | Orbimed Advisors | USD 25m | 0.5% |
| 6 | Hyperion Capital Advisors | USD 728,000 | 0.3% |
| 7 | Bayforest Capital | USD 317,000 | 0.3% |
| 8 | Landscape Capital Management | USD 4.3m | 0.3% |
| 9 | Oxford Asset Management LLP | USD 510,000 | 0.3% |
| 10 | Holocene Advisors | USD 99m | 0.2% |
West Pharmaceutical Services Inc trades under the symbol WST on the New York Stock Exchange. Its CUSIP, the code used on Form 13F, is 955306105.
41 of the 720 hedge fund managers PPLI.com tracks reported West Pharmaceutical Services Inc shares on Form 13F for 30 June 2026. The largest reported positions were held by Artisan Partners (USD 866m), Citadel Advisors (USD 127m), POINT72 Asset Management (USD 102m), Holocene Advisors (USD 99m) and Marshall Wace LLP (USD 30m).
41 managers in our coverage reported it, and between them they run 491 funds with a file on PPLI.com. The count is of managers, because Form 13F is filed by the firm and not by each fund.
Alpine Peaks Capital, where the position was 8.1% of the reported 13F book at 30 June 2026.
No. Form 13F reports long positions in U.S.-listed shares and options. Short positions are not disclosed in it.
Positions are taken by PPLI.com from Form 13F filings with the U.S. Securities and Exchange Commission for the quarter shown. They are reported by each manager, cover all of its accounts and may have changed since. PPLI.com has no relationship with West Pharmaceutical Services Inc or with the managers listed.
Nothing here is investment, tax or legal advice, a recommendation, or an offer or solicitation to buy or sell any security. To report an error, write to the editor.
Read our Privacy Policy before submitting. Share only the information needed to describe your question; do not include medical records or account credentials.